Mumbai, January 23, 2026: Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA, BSE: 524715) on Friday announced that it has received approval to manufacture and market a generic version of semaglutide injection in India, marking a significant step in expanding access to advanced therapies for chronic weight management.
The company said the product will be introduced in the Indian market after the expiry of the semaglutide patent. The generic semaglutide injection will be marketed under the brand name Noveltreat and is intended for use in adults as part of a reduced-calorie diet and increased physical activity regimen.
Product Details and Dosage Profile
Noveltreat will be available in five dose strengths, providing flexibility across treatment stages. These include 0.25 mg, 0.5 mg and 1 mg doses in 0.5 mL pens, along with 1.7 mg and 2.4 mg doses in 0.75 mL pens. The recommended maintenance dose is 2.4 mg administered once weekly.The injection is delivered through a prefilled pen designed for ease of use and accurate dosing, supporting patient adherence in long-term weight management therapy.
Clinical Validation and Strategic Rationale
The approval follows a Phase III clinical trial conducted in India, which evaluated the efficacy and safety of the therapy for chronic weight management. Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, widely used in the management of metabolic conditions.Commenting on the development, Kirti Ganorkar, Managing Director of Sun Pharma, said the rising prevalence of obesity and diabetes in India has created a pressing need for effective and accessible treatment options. He added that the company aims to leverage its leadership in cardiometabolic therapies to improve nationwide access to generic semaglutide after patent expiry.
Medical experts also highlighted that GLP-1 based therapies represent an important advancement in metabolic health and should be used alongside lifestyle interventions such as diet and physical activity, under appropriate medical supervision.
Broader Semaglutide Portfolio
Separately, the company had earlier received approval in December 2025 to manufacture and market semaglutide injection for adults with insufficiently controlled type 2 diabetes mellitus. That product will be launched under the brand name Sematrinity, also following patent expiry in India.About the Company
Sun Pharmaceutical Industries Limited is India’s largest pharmaceutical company and a leading global specialty generics player, with operations spanning specialty, generics and consumer healthcare products. The company has a presence in over 100 countries, supported by vertically integrated manufacturing facilities across six continents, and a growing global specialty portfolio in dermatology, ophthalmology and oncology.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.